Overview
NICE is unable to make a recommendation on nintedanib (Ofev) for treating fibrosing interstitial lung disease in people 6 to 17 years. This is because the company did not provide an evidence submission.
Last reviewed: 19 November 2025
Next review: We will review this decision if the company decides to make a submission.